In fact, Belapectin, a Gal-3 inhibitor, has also been investigated in individuals with advanced fibrosis with promising results regarding lowering of hepatic venous pressure gradient and development of varices, but with no significant changes in liver fibrosis compared to placebo [27]. The gene discussed is LGALS3; the disease is varicose disease.